Finally, regarding the effect of BemA as a PPARα agonist; although PPARα is less abundant in human liver than in rodents [41], its expression in the liver of NASH patients is negatively correlated with the severity of steatosis and inflammation, and histological improvement is strongly associated with an increase in hepatic PPARα expression [42]. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.